Compare Invesco Preferred ETF (PGX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs Repligen Corporation Common Stock — how do they compare? Invesco Preferred ETF trades at $9.93 (market cap $3.58B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 3.1× Invesco Preferred ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Preferred ETF for 96 Days and Repligen Corporation Common Stock for 0 Days on average.
| PGX | RGEN | |
|---|---|---|
Market Cap | $3.58B | $11.14B |
Volume | 10,976,352 | 1,259,263 |
52-Week High | $11.61 | $194.57 |
52-Week Low | $9.95 | $102.87 |
Typical Hold Time | 96 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $9.98 with a modest 0.3% daily gain, though technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The stock faces significant resistance at $10, which also serves as multiple support levels. Recent corporate actions include scheduled dividends of $0.06 per share for H2-2026, providing income potential for shareholders.
The outlook remains cautious given the bearish technical setup and lack of available fundamental data. While dividend payments offer some investor appeal, the absence of key valuation metrics and financial ratios creates uncertainty about the company's underlying business performance and competitive positioning.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
